http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9745426-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3419f8dffceb3283c8829bc17bfe1018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e10582df78ee21c9b7c4f2eaf9c8cf4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24ec1cdc78f3808297cf884b92b95e0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35cc2f7e1db9cb302d95855942a49988 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 |
filingDate | 1997-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77c00fe8e500684ccfec83bdc0513577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0255660856a736a67a096362093f297b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9eb2dec2d065b490db533538db2728e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c01dee3fff232af6d497d03a25f03ef |
publicationDate | 1997-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-9745426-A1 |
titleOfInvention | Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists |
abstract | A class of substituted azetidine, pyrrolidine and piperidine derivatives of formula (I) are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists, wherein Z represents an optionally substituted six-membered heteroaromatic ring selected from pyridine, pyrazine, pyrimidine and pyridazine; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 4 carbon atoms, optionally substituted in any position by one or more substituents selected from fluoro and hydroxy; T represents nitrogen or CH; U represents N or CR2. V = O, S or NR3. M & R are as defined in the application. |
priorityDate | 1996-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 551.